pharma · Asthma · Multiple Sclerosis · TEVA
Teva Pharma
Teva Pharma GmbH
NovaPharmaNews editorial coverage mentioning Teva Pharma — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- 10 Dornierstr., Ulm, Donau, 89079, DE, TEL AVIV
- Employees
- 126
- Programs
- 473
- Drugs
- 447
- Patents
- 454
News & analysis
NovaPharmaNews articles mentioning Teva Pharma — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Teva Pharma — regulatory, clinical, and market analysis.
Teva's Olan EMA Application Acceptance: Strategic Implications for Pharma
Teva Pharmaceuticals has received acceptance from the European Medicines Agency (EMA) for its marketing authorization application for Olan. This pivotal regulatory step signals a deeper review process and potential market entry, with significant implications for the pharmaceutical industry.
Teva's Once-Monthly Schizophrenia Shot Enters EMA Review, Signaling New Treatment Option
The European Medicines Agency (EMA) has accepted Teva Pharmaceuticals and Medincell's marketing authorization application for their once-monthly olanzapine long-acting injectable (LAI) for the treatment of schizophrenia in adults. This regulatory milestone signifies a potential new adherence-focused treatment option for patients in Europe.